Skip to content
ClinCalc Pro
Menu
Glomerulonephritis / Vasculitis

Methylprednisolone IV Pulse (Nephrology)

Brand names: Solu-Medrone

Intravenous pulse methylprednisolone is a high-potency glucocorticoid regimen used in nephrology to induce rapid immunosuppression in severe glomerular and immune-mediated renal disease, such as crescentic glomerulonephritis and vasculitis.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

As a synthetic corticosteroid, it binds glucocorticoid receptors to broadly suppress inflammatory and immune responses, reducing cytokine production and inflammatory cell activity.

Prescribing in practice

  • High-dose pulses can cause serious acute effects including hyperglycaemia, hypertension, fluid retention, infection risk and, rarely, arrhythmia, so patients require close monitoring during and after infusion.
  • Screen for and manage active infection before pulsing, and consider gastroprotection and bone protection as appropriate.
  • It is given intravenously, usually over consecutive days, under specialist supervision.

Monitoring

Monitor blood pressure, blood glucose, fluid balance, electrolytes and for signs of infection during and following pulse therapy.

Counselling the patient

  • You may notice flushing, a metallic taste, raised blood sugars or sleep disturbance around the infusions.
  • Report fever or other signs of infection promptly, as steroids increase infection risk.
  • Do not stop any prescribed continuing steroid abruptly without medical advice.

Evidence & guidelines

Pulsed methylprednisolone is a standard component of induction immunosuppression for severe ANCA-associated vasculitis and rapidly progressive glomerulonephritis.

Reference: KDIGO Vasculitis 2021; KDIGO Lupus Nephritis 2021; NICE NG232; SPC Solu-Medrone; Confirm identity and dosing against the manufacturer SPC (eMC) and NICE. Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.